Placebo of CDP870

DRUG3 trials

Sponsors

Otsuka Pharmaceutical Co., Ltd., Korea Otsuka Pharmaceutical Co., Ltd.

Conditions

Rheumatoid Arthritis

Phase 2

Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

CompletedNCT00791999

Otsuka Pharmaceutical Co., Ltd.Rheumatoid Arthritis

Start: 2008-11-30End: 2011-01-31Updated: 2012-08-10

Phase 3

Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

CompletedNCT00791921

Otsuka Pharmaceutical Co., Ltd.Rheumatoid Arthritis

Start: 2008-11-30End: 2010-01-31Updated: 2012-08-07

A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis

CompletedNCT00993317

Korea Otsuka Pharmaceutical Co., Ltd.Rheumatoid Arthritis

Start: 2009-10-31End: 2011-08-31Updated: 2012-09-27

Related Papers

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials

International Journal of Rheumatic Diseases2023-05-1713 citations

Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.

2013-12-0947 citations

Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.

2013-11-0140 citations